Enhanced Recovery After Surgery (ERAS) in Patients Undergoing Emergency Laparotomy
Launched by TIANJIN MEDICAL UNIVERSITY · Dec 12, 2023
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a method called Enhanced Recovery After Surgery (ERAS) to see if it can help patients recover better after emergency surgeries, specifically emergency laparotomies, which are operations to address serious abdominal issues. The researchers want to find out if ERAS is safer and more effective than standard care practices. To do this, patients who qualify will be randomly assigned to either the ERAS group or the conventional care group during their surgery and recovery period.
To be eligible for the study, patients need to be between 18 and 70 years old and must have had a preoperative examination that confirms they need emergency surgery within a specific time frame after arriving at the hospital. Participants can expect to receive either the ERAS treatment or standard care, and their recovery will be monitored to see how well they do. It’s important to note that certain conditions, like severe infections or specific medical histories, may prevent someone from participating in the trial. If you or a loved one are considering joining this study, it’s a great opportunity to contribute to research that may improve recovery after surgery for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients between the ages 18-70,
- • Patients who completed the preoperative examination and preoperative diagnosis within 4 hours after admission for acute abdomen diseases,
- • Required emergency surgery within 6 hours from surgeon encounter.
- Exclusion Criteria:
- • Patients who refused to be enrolled in this study;
- • Patients with any psychiatric or neurological disorders;
- • Pseptic shock at admission;
- • Duration of symptoms more than five days;
- • Patients with contraindications to the placement of lumbar epidural catheters, such as coagulation disorders, severe sepsis, etc.;
- • Presence of preoperative factors affecting wound healing (e.g. long-term steroid use);
- • Patients with extra-abdominal injuries or terminal malignancy, or patients requiring damage control surgery;
- • Patients found intraoperatively to require any procedure other than splenectomy, partial hepatectomy or liver repair, bowel resection and anastomosis, laparoscopic cholecystectomy and appendectomy, and gastrointestinal perforation repair.
About Tianjin Medical University
Tianjin Medical University is a prestigious institution dedicated to advancing medical science and healthcare through innovative research and education. As a leading clinical trial sponsor, the university is committed to conducting rigorous and ethically sound clinical studies that aim to enhance patient outcomes and contribute to the global body of medical knowledge. With a focus on collaboration and interdisciplinary approaches, Tianjin Medical University leverages its extensive resources and expertise to support the development of new therapies and improve clinical practices across a wide range of medical disciplines.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tianjin, Tianjin, China
Patients applied
Trial Officials
Hong Zheng, MD
Study Chair
Tianjin First Central Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported